Drug
Tropifexor clinical trials
Also written LJN452.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
8 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tropifexor is read from its arms, and is right about nine times in ten.
Testing it · 8
- Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.TerminatedPhase 2Novartis PharmaceuticalsNCT04065841Written as Tropifexor
- Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)TerminatedPhase 2Novartis PharmaceuticalsNCT04147195Written as Tropifexor
- Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisCompletedPhase 2Novartis PharmaceuticalsNCT03517540Written as Tropifexor (LJN452)
- The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.CompletedPhase 1Novartis PharmaceuticalsNCT04408937Written as triopifexor
- Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)TerminatedPhase 2Novartis PharmaceuticalsNCT02855164Written as Tropifexor (LJN452)
- To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.CompletedPhase 2Novartis PharmaceuticalsNCT02713243Written as LJN452
- A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02516605Written as Part 1: LJN452
- Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT03681457Written as LJN452
Codes
What other systems call tropifexor · ClinicalTrials.gg INT001067
- MeSH (NLM) C000630573tropifexorOne source NLM
- UNII (FDA) NMZ08KM76ZTROPIFEXORConfirmed FDA, NLM, Wikidata
- Wikidata Q63862124tropifexorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152764TropifexorOne source FDA
- DrugBank DB16343One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630573 | tropifexor | One source NLM |
| UNII (FDA) | NMZ08KM76Z | TROPIFEXOR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q63862124 | tropifexor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152764 | Tropifexor | One source FDA |
| DrugBank | DB16343 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.